US FDA Has Model Drug Facts Labels For OTC Naloxone, Needs Switch Proposals

 
• By Malcolm Spicer

Development of the model DFLs was a first for agency. The project was "part of our broader commitment to addressing the opioid crisis" and should help sponsors with potential naloxone OTC switch NDAs, says Commissioner Scott Gottlieb.

USPills
Model Drug Facts label project may help FDA address opioid crisis • Source: Shutterstock

More from Marketing & Advertising

More from Compliance